StockUS listing USKZIANASDAQHealthcareProfitless Growth

Kazia Therapeutics Ltd ADR(KZIA) Stock Analysis | Healthcare

USD --+0.00%
Reward53Moderate
Risk72High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 76.50M
Reward Ratingⓘ53 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KZIA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kazia Therapeutics Ltd ADR?

Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel.

AI Brief Pro

The brief on Kazia Therapeutics Ltd ADR

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Kazia Therapeutics Ltd ADR?

Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 76.50M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.356
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.